• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

DF/HCC News

    Cancer pioneer Judah Folkman, MD, dies at 74

    DF/HCC member and cancer research pioneer Judah Folkman, MD, passed away on Jan

    Tissue Microarray Core has re-opened and added services

    As of December 3rd, all requests for Tissue Microarray and Nucleic Acid Isolation services should be submitted to the DF/HCC Tissue Microarray Core.  The core remains under the direction of Jon Aster, MD, PhD

    Nanoparticles on cell
    Brigham and Women's Hospital: Signature strengths advance cancer research

    Brigham and Women’s Hospital, renowned for excellence in patient care, research, and teaching, traces its roots in medicine back to 1832

    JeffClark
    Q&A with Jeff Clark: Recent steps streamline clinical trials process

    The appointment of Jeffrey Clark, MD (MGH) as medical director of Clinical Trials Operations at DF/HCC became official about two months ago, but the helm is hardly new to him

    Wilms tumor with a WTX deletion
    “X” marks the spot for new Wilms’ tumor gene

    When investigators went hunting for a gene implicated in Wilms’ tumor – the most common pediatric kidney cancer – they found it in an unlikely spot

    Histopathologic correlation of Sorafenib
    Circumventing angiogenic escape mechanisms in kidney cancer

    Much like Houdini, who freed himself from handcuffs and shackles, tumors find clever routes of escape from VEGF receptor inhibitors, a new class of drugs heralded for prolonging the survival of patients with renal cell carcinoma (RCC), the most common kidney cancer. In recent months, a team of DF/HCC investigators has been studying these angiogenic escape mechanisms and searching for new therapies to circumvent them

    Thirty-Eight New Members Join DF/HCC

    Thirty-eight individuals from our seven member institutions have recently joined DF/HCC

Displaying results 155 to 161 out of 207